-
FDA Approves 177Lu-PSMA-617 for Pretreated PSMA+ Metastatic Castration-Resistant Prostate Cancer
Based on data from the phase 3 VISI...
2022-03-24 10:16:03 -
Adjuvant CDK4/6 Inhibitors Demonstrate Success in Early-Stage HR+ Breast Cancer Development
CDK4/6 inhibitors in the metastatic...
2022-03-08 17:12:53 -
Sacituzumab Govitecan Significantly Improves PFS Vs Chemo in HR+ Metastatic Breast Cancer
Sacituzumab govitecan resulted in a...
2022-03-08 16:21:30 -
Frontline Poziotinib Produces Clinically Meaningful Efficacy in NSCLC Harboring HER2 Exon 20 Insertion Mutations
Poziotinib elicited encouraging...
2022-03-08 15:59:29 -
Tamoxifen Plus Extended Letrozole Improves DFS in Postmenopausal Breast Cancer
Initial treatment with tamoxife...
2022-03-08 15:56:50 -
Ivosidenib/Azacitidine Granted Priority Review Designation by FDA for IDH1+ AML
A supplemental new drug application...
2022-03-08 13:46:43 -
Adjuvant Pembrolizumab Improves Distant Metastasis–Free Survival in Resected Stage IIB and IIC Melanoma
Pembrolizumab significantly improve...
2022-03-08 13:46:39 -
First-ever malaria vaccine recommendation now published in a position paper and in the WHO guidelines for malaria
WHO today published anupdated posit...
2022-03-07 17:47:17 -
Risk-Adaptive Approaches Offer Safer, Effective Strategies for Early-Stage HER2+ Breast Cancer
The integration of HER2-targete...
2022-03-07 17:21:14 -
Employers Highlight Barriers to Biosimilar Adoption
The promise of large savings du...
2022-03-07 17:15:29